RCEL AVITA Medical, Inc. Insider Trading

Director Joseph Fralin Woody purchased 5.2K shares of RCEL at $4.00; stock now down 42.1% from 52-week high amid ongoing losses.

Joseph Fralin Woody, a director, purchased 5,200 shares at $4.00 on 2026-06-09, increasing his holdings from 102.8K to 108.0K shares. The transaction occurs as RCEL trades -42.1% from its 52-week high of $7.12 and -5.7% over the prior 30 days. AVITA Medical remains unprofitable with net income of $-10.6M in the latest quarter despite annual revenue growth of +11.4%; the company's market cap is $126.8M. At the same ticker, Woody's prior three measurable buys showed mixed outcomes (2 of 3 well-timed at the 90-day mark), though his cross-ticker track record reflects an average 90-day return of -1.8% with a 33.33% win rate across 8 prior buys. The purchase into a depressed valuation in a loss-making, small-cap biomedical device company presents a data point for investors monitoring director conviction relative to near-term price momentum and fundamental trajectory.

RCEL Director Woody buys 10,000 shares in 2 transactions at $4.20 and $4.18 (avg $4.19)—stock near 52-week lows.

Director Joseph Fralin Woody purchased 10,000 shares across 2 separate transactions on 2026-06-09 at blended average price of $4.19, increasing his holdings from 92.8K to 102.8K shares (+10.8%). The purchase prices ($4.20 and $4.18) align closely with the current price of $4.12, positioning the transaction near the lower end of the 52-week range ($3.22–$7.12) and well below the 52-week high by 42.1%. AVITA Medical reported $19.3M in revenue for the latest quarter with a net loss of $-10.6M and negative full-year profitability, while achieving 11.4% annual revenue growth. The modest transaction size relative to his existing 92.8K-share position and the unprofitable fundamental backdrop limit the significance of this purchase as a broad conviction indicator.

Director Joseph Fralin Woody buys 10,000 shares at RCEL for $40,949.00 amid -41.3% decline from 52-week high

Director Joseph Fralin Woody purchased 10,000 shares totaling $40,949.00 across 2 transactions on 2026-06-03 at prices of $4.10 and $4.09, raising his holdings from 82.8K shares to 92.8K shares (+12.1%). The purchase occurs in a context of significant stock weakness: the current price of $4.18 is -41.3% from the 52-week high of $7.12, and the stock has declined -5.4% over the past 30 days and -12.0% over 90 days. The company remains unprofitable with net income of $-10.6M against quarterly revenue of $19.3M, though annual revenue growth stands at +11.4%. The director's accumulation while the stock trades well below its recent peak suggests conviction, though the underlying profitability headwind limits the signal strength.

Director Joseph Fralin Woody purchases 20,000 shares (20.0K shares) across 4 transactions for $84,936.50 at average $4.25

Joseph Fralin Woody, a Director, made 4 separate purchases totaling 20,000 shares for $84,936.50 at a blended average price of $4.25 on June 1-2, 2026. His post-transaction holding of 20,000 shares represents a full acquisition from zero prior position. The stock currently trades at $4.16, down 2.8% over 30 days and 13.0% over 90 days, and sits -41.6% from its 52-week high of $7.12. Against this context, the purchase prices of $4.18–$4.34 are modest premiums to the current market, but the company faces material profitability challenges: it reported a quarterly revenue of $19,251,000.00 with a net loss of $-10,611,000.00, and was unprofitable over its most recent full fiscal year. The transaction's significance is tempered by the lack of prior holdings, the absence of pattern or magnitude to establish conviction, and the company's ongoing operational losses despite 11.4% annual revenue growth.

RCEL CFO O'Toole buys 1,800 shares at $4.78; stock +36.0% in 90 days but insider's prior trades at ticker 0-for-4 well-timed, company unprofitable.

CFO David D O'Toole purchased 1,800 shares of RCEL at $4.78 on 2026-03-11, adding 1.3% to holdings of 140,127 shares. While the stock has gained 36.0% over the past 90 days and currently trades at $4.80, his prior transaction history at RCEL provides limited confidence in timing insight: 4 prior measurable buys at this ticker yielded 0 outcomes with positive 90-day returns, with 90-day returns ranging from -34.6% to -17.0%. Separately, his cross-ticker track record shows 20 prior buys averaging +5.3% over 90 days with a 47.37% win rate, indicating modest baseline skill. The company itself remains unprofitable with a net loss of $13.2M against $17.1M quarterly revenue, which limits interpretation of the buy as a strong conviction signal.

CFO O'Toole buys 3,000 RCEL shares at $4.15; stock now $4.85. All 5 prior same-ticker buys generated negative 90d returns.

David D. O'Toole, CFO of AVITA Medical, purchased 3,000 shares at $4.15 on 2026-02-19, representing a 2.2% increase to his 140,127-share position. While the stock has risen 9.2% over the past 30 days and 29.3% over 90 days from lower base levels, his same-ticker history presents a notable pattern: all 5 prior buys at RCEL produced negative 90-day returns, ranging from -17.0% to -34.6%, with 0 of 5 classified as well-timed. The company remains unprofitable on a full-year basis with $-13.2M net income against $17.1M quarterly revenue. This repeated timing pattern at this specific ticker—coupled with ongoing losses—warrants examination of whether the CFO's purchase decisions have consistently preceded further declines.

Director McNamara buys 10,000 RCEL shares at $4.50 amid -69.1% decline from 52-week high; stock down 19.0% in 30 days.

McNamara (Director) purchased 10,000 shares at $4.50 on 2025-08-28, increasing his holdings by 13.0% to 86,771 shares total. The purchase occurs at $4.50 while the current price is $4.34, and the stock is -69.1% from its 52-week high of $14.06 and down 19.0% over 30 days. However, McNamara's cross-ticker track record shows 3 prior buys with an average 90-day return of -32.0% and a 90-day win rate of 0.00%, suggesting a pattern of purchasing before further declines. At RCEL specifically, his 2 prior measurable buys (2025-03-06 and 2025-02-20) both delivered negative returns at the 90-day mark (-28.6% and -35.4% respectively), with 0 of 2 being well-timed. The company remains unprofitable with a net loss of -$9.9M on quarterly revenue of $18.4M, despite 28.1% annual revenue growth. The timing and context raise questions about conviction in a fundamentally challenged asset trading near recent lows.

CFO O'Toole bought 2,000 RCEL shares at $4.52; stock down 67.6% from 52-week high, 0 of 4 prior buys well-timed.

O'Toole David D, CFO of AVITA Medical, purchased 2,000 shares at $4.52 on 2025-08-26, adding 6.7% to his existing position. The purchase occurs with the stock trading 67.6% below its 52-week high and down 21.0% in the 30 days prior to the trade. At RCEL specifically, O'Toole's prior 4 measurable buys (spanning December 2024 through February 2025) showed 0 instances of positive 90-day returns, with cumulative losses ranging from -31.3% to -34.6% over the 90-day horizon. The company is currently unprofitable with a net income of $-9.9M against quarterly revenue of $18.4M, though annual revenue growth stands at 28.1%. The repeated purchase pattern at depressed valuations paired with consistent 90-day underperformance at this specific ticker suggests price weakness has persisted despite prior accumulation.

Director McNamara buys 10,000 RCEL shares at $5.00 amid -66.6% decline from 52-week high; prior same-ticker buys underwater.

Director Robert McNamara purchased 10,000 shares of AVITA Medical (RCEL) at $5.00 on 2025-08-19, increasing his holdings by 15.0% to 76.8K shares. The stock is currently trading at $4.69, down 66.6% from its 52-week high of $14.06 and down 10.0% over the past 30 days. Notably, McNamara's two prior purchases at RCEL (on 2025-03-06 and 2025-02-20) both remain significantly underwater at the 90-day mark, with negative 90-day returns of -28.6% and -35.4% respectively, and his cross-ticker buy history shows 0 of 2 prior trades with positive 90-day outcomes (average 90d return: -32.0%). The company is unprofitable with net income of -$9.9M against $18.4M quarterly revenue, although annual revenue growth stands at +28.1%. This purchase occurs within a context of persistent stock deterioration and a demonstrated pattern of poorly-timed acquisitions at this ticker.

CFO O'Toole buys 2,000 RCEL shares at $4.81; all 5 prior RCEL buys by him posted negative 90d returns.

CFO David D O'Toole purchased 2,000 shares of AVITA Medical at $4.81 on 2025-08-12, raising his holdings to 29,657 shares. However, his transaction-timing record at this ticker is notably unfavorable: across his 5 prior purchases at RCEL, 0 of 5 delivered positive 90-day returns, with losses ranging from -1.0% to -34.6%. The current stock price of $5.52 is 60.7% below the 52-week high of $14.06, and AVITA is unprofitable with net income of $-9.9M against $18.4M quarterly revenue. This purchase follows a 17.5% decline over the prior 90 days and extends a pattern where the CFO's prior RCEL accumulations consistently underperformed within their post-purchase 90-day windows.